Forte Biosciences Accepts Resignation of Director David Veitch

Forte Biosciences Inc. reported that independent director David Veitch resigned from the board effective June 1 2026 according to an 8-K filed with the SEC on June 2 2026.

The company listed no disagreement with Veitch on any matter relating to its operations policies or practices. Item 5.02 of the filing states only that the board accepted the resignation.

Forte Biosciences now operates with one fewer director. The filing does not disclose the prior board size or whether the company intends to fill the vacancy. As a Nasdaq-listed issuer Forte must maintain compliance with board independence and committee-composition rules; any resulting gap requires remediation within the exchange's standard cure periods.

The resignation also activates downstream reporting and governance mechanics. Forte must update its director and officer questionnaires and insider lists and consider whether the change affects its Compensation Committee or Audit Committee assignments. Future proxy statements will reflect the reduced board composition for the 2027 annual meeting cycle. No immediate shareholder vote is required.

In the same filing Forte reported results from its annual shareholder meeting under Item 5.07 though specific vote tallies were not detailed in the primary Form 8-K exhibit. Item 9.01 incorporates exhibits that contain the full text of the board resolutions accepting the resignation.

This marks the latest board-level change at Forte Biosciences a clinical-stage company focused on dermatology assets. Public companies file Form 8-K within four business days of director departures under Item 5.02 to provide investors and regulators timely notice of governance shifts that can affect oversight of strategy clinical programs and capital allocation.